Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Deep Vein Thrombosis Prophylaxis Condition: Abdominal surgery |
Dose: Subcutaneous Injection – 40 mg Frequency: once daily Duration: 7 to 10 days; up to 12 days has been administered in clinical trials or until risk of deep vein thrombosis has diminished Note: Initiate 2 hours preoperatively. |
|
Indication: Deep Vein Thrombosis Prophylaxis Condition: Knee or hip replacement surgery |
Dose: Subcutaneous Injection – 30 mg Frequency: every 12 hours Duration: 7 to 10 days; up to 14 days has been administered in clinical trials or until risk of deep vein thrombosis has been significantly reduced or patient is on anticoagulant therapy; initiate therapy 12 to 24 hours postoperatively and continued for 10 days or up to 35 days postoperatively Note: Duration of administration is 7 to 10 days; up to 14 days has been administered in clinical trials or until risk of DVT has diminished. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Child |
Dose: Form – No approved pediatric dosage available Note: No approved pediatric dosage available |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Prophylaxis in abdominal surgery Condition: Severe renal impairment (Creatinine Clearance less than 30 mL/minute) |
Dose: Subcutaneous Injection – 30 mg Frequency: once daily Note: Dosage reductions required |
|
Indication: Prophylaxis in hip or knee replacement surgery Condition: Severe renal impairment (Creatinine Clearance less than 30 mL/minute) |
Dose: Subcutaneous Injection – 30 mg Frequency: once daily Note: Dosage reductions required |
Administration
- Given by subcutaneous injection
- Inject into fatty tissue of abdomen
Side Effect
- Hemorrhage (1-4%)
- Elevation of serum aminotransferases (6%)
- Fever (5-8%)
- Local site reactions (2-5%)
- Thrombocytopenia (3%)
- Nausea (3%)
- Anemia (2%)
- Ecchymosis (3%)
- Atrial fibrillation
- Heart failure
- Pulmonary edema
- Pneumonia
- Haemorrhagic complications
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Anticoagulants (Warfarin, Heparin, Dabigatran, Rivaroxaban, Apixaban, Edoxaban), Platelet aggregation inhibitors (e.g. dipyridamole, salicylates, NSAIDs (Ibuprofen, Naproxen, Diclofenac, Celecoxib, Meloxicam, Indomethacin, Piroxicam, Ketorolac), sulfinpyrazone)
|
Increased risk of bleeding
|
|
Vitamin E
|
May increase bleeding
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Major Clotting Disorders like History of Thrombocytopenia
|
Increased bleeding risk
|
|
Active Gastro-Intestinal Ulcer
|
Risk of severe bleeding
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store in a cool and dry place, protect from light and moisture. Do not store above 25°C. Do not store in a refrigerator or freezer. Keep out of the reach of children
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.